Antibiotic Treatment for Klebsiella UTI

Treatment Guidelines

• The European Urology Association recommends oral fluoroquinolones (ciprofloxacin 500-750 mg twice daily for 7 days or levofloxacin 750 mg daily for 5 days) as first-line empiric therapy for uncomplicated Klebsiella UTI if local resistance is <10% 1
• For uncomplicated Klebsiella UTI, oral cephalosporins (cefpodoxime 200 mg twice daily for 10 days) are recommended if fluoroquinolone resistance is higher 1
• The European Urology Association suggests trimethoprim-sulfamethoxazole 160/800 mg twice daily for 14 days as an alternative for uncomplicated Klebsiella UTI if local resistance is <20% and the patient has not used this antibiotic in the previous 3-6 months 1
• Initial parenteral therapy with ceftriaxone followed by oral step-down is recommended for uncomplicated pyelonephritis due to Klebsiella 1
• The treatment duration for uncomplicated pyelonephritis due to Klebsiella is 7-10 days for most cases 1
• For complicated UTI due to Klebsiella, the treatment duration is 7-14 days (14 days for men when prostatitis cannot be excluded) 1
• Empiric parenteral options for non-resistant strains of complicated UTI due to Klebsiella include ceftriaxone 1-2 g once daily 1
• The European Urology Association recommends obtaining urine culture and susceptibility testing before finalizing therapy for complicated UTI due to Klebsiella 1
• For simple cystitis due to carbapenem-resistant Klebsiella, single-dose aminoglycoside (amikacin or gentamicin) is recommended as first-line therapy 2, 3
• For complicated UTI due to carbapenem-resistant Klebsiella, ceftazidime-avibactam 2.5 g IV every 8 hours is a preferred newer agent 2, 3
• The European Urology Association recommends avoiding third-generation cephalosporins for empiric treatment of Klebsiella UTI due to high resistance rates 3
• Infectious disease consultation is highly recommended for multidrug-resistant organism infections 3

Special Considerations

• Automated susceptibility testing may not be reliable for multidrug-resistant organisms, and Etest minimum inhibitory concentrations should be considered for critical cases 3
• Tigecycline monotherapy should be avoided for bloodstream infections due to suboptimal outcomes 3

Treatment of Klebsiella pneumoniae Urinary Tract Infections

ESBL-Producing Klebsiella pneumoniae UTI

• Beta-lactam/beta-lactamase inhibitors (BLBLI) provide moderate-certainty evidence for non-inferiority to carbapenems in pyelonephritis caused by third-generation cephalosporin-resistant Enterobacterales 4

Carbapenem-Resistant Klebsiella pneumoniae (CRE) UTI

• Aminoglycosides are superior to tigecycline for cUTI caused by CRE (moderate certainty of evidence) 5
• Ceftazidime-avibactam is a preferred newer agent for complicated UTI due to CRE 6
• Meropenem-vaborbactam is recommended as a treatment option for CRE-UTI 6
• Imipenem-cilastatin-relebactam is recommended as a treatment option for CRE-UTI 6
• Plazomicin is recommended as a treatment option for CRE-UTI 6
• Meropenem-vaborbactam or ceftazidime-avibactam are recommended for severe CRE infections if active in vitro (conditional recommendation, moderate and low certainty of evidence, respectively) 4
• Aminoglycosides are preferred over tigecycline for cUTI caused by CRE 4, 5

Special Considerations

• Aminoglycosides achieve urinary concentrations exceeding peak plasma levels by 25- to 100-fold, making them highly effective for UTIs 6
• Single-dose aminoglycoside therapy is effective for lower urinary tract infections with microbiologic cure rates of 87-100% 6
• Aminoglycosides have shown better clinical outcomes compared with tigecycline-containing regimens for CRE UTI 5